Tradestie Institutional Equity Comparison Engine

QLTI vs MYGN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MYGN Overall Edge

MYGN Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Myriad Genetics Inc (MYGN) driven by superior Valuation, Growth & Margin, Options & Structure while QLTI counters with relative strength in Momentum & Technical. Fundamentally, QLTI trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus MYGN at 54.0x Forward P/E and -13.3% operating margin (-1.5% YoY). In options structure, QLTI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against MYGN sits in SURGE (22nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MYGN
QLTI N/M vs MYGN 54.0x Fwd P/E
Growth & Margin Winner MYGN
Op Margin N/A vs -13.3% ยท YoY N/A vs -1.5%
Momentum & Technical Winner QLTI
1Y +7.0% vs -12.3% ยท 52W Pos 86% vs 53%
Options & Structure Winner MYGN
UNCLASSIFIED (N/A IV) vs SURGE (22nd %ile IV)
QLTI NYSE Arca
GMO International Quality ETF
Institutional Equity
$28.11
-0.81% 1D
Market Cap N/A
1M Return +2.85%
1Y Return +6.95%
Forward P/E N/M
Unified AI Score
47.8 / 100 HOLD
Tech 50.0 Fund 35.0 Flow 50.0 Mom 11.1
MYGN NASDAQ
Myriad Genetics Inc
In Vitro & In Vivo Diagnostic Substances
$5.57
-1.59% 1D
Market Cap $542.9M
1M Return +39.95%
1Y Return -12.28%
Forward P/E 54.0x
Unified AI Score
46.2 / 100 HOLD
Tech 30.0 Fund 43.0 Flow 56.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: QLTI +6.95% MYGN -12.28% Spread: +20.35 pp (QLTI Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
QLTI TTM Op. Margin: N/A MYGN TTM Op. Margin: -13.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QLTI vs MYGN. Trailing 12-month operating profitability (QLTI N/A vs MYGN -13.3%) and valuation multiples (QLTI N/M vs MYGN 54.0x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: QLTI (3) vs MYGN (7)
Institutional Metric QLTI MYGN Criterion Row Winner
Market Capitalization Scale N/A $542.9M Larger Scale MYGN
Trailing P/E Ratio Valuation N/M 54.0x Lower Multiple MYGN
Forward P/E Ratio Valuation N/M 54.0x Lower Multiple MYGN
Revenue Growth (YoY) Growth N/A -1.5% Higher Growth MYGN
Operating Margin (TTM) Profitability N/A -13.3% Higher Margin MYGN
Net Profit Margin Profitability N/A -16.1% Higher Margin MYGN
Return on Equity (ROE) Capital Efficiency N/A -40.2% Higher ROE MYGN
52-Week Range Position Momentum 86% ($24โ€“$29) 53% ($3โ€“$8) Stronger Trend QLTI
Beta / 30D Volatility Risk Regime 0.81ฮฒ ยท 16% Vol 0.68ฮฒ ยท 122% Vol Lower Realized Risk QLTI
Unified Institutional Score Composite Signal 47.8 / 100 (HOLD) 46.2 / 100 (HOLD) Higher Composite QLTI

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full QLTI vs MYGN Buy Guide
QLTI UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live QLTI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MYGN SURGE
12d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 22nd %ile
IV Regime Compressed (<25th %ile)
Live MYGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither QLTI nor MYGN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.